JP2024503635A5 - - Google Patents
Info
- Publication number
- JP2024503635A5 JP2024503635A5 JP2023541262A JP2023541262A JP2024503635A5 JP 2024503635 A5 JP2024503635 A5 JP 2024503635A5 JP 2023541262 A JP2023541262 A JP 2023541262A JP 2023541262 A JP2023541262 A JP 2023541262A JP 2024503635 A5 JP2024503635 A5 JP 2024503635A5
- Authority
- JP
- Japan
- Prior art keywords
- pro
- cys
- pharmaceutically acceptable
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21150562.3A EP4050018A1 (en) | 2021-01-07 | 2021-01-07 | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EPEP21150562 | 2021-01-07 | ||
| PCT/EP2022/050294 WO2022148851A1 (en) | 2021-01-07 | 2022-01-07 | Compounds comprising a fibroblast activation protein ligand and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503635A JP2024503635A (ja) | 2024-01-26 |
| JP2024503635A5 true JP2024503635A5 (enExample) | 2025-01-16 |
Family
ID=74215696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541262A Pending JP2024503635A (ja) | 2021-01-07 | 2022-01-07 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240115745A1 (enExample) |
| EP (2) | EP4050018A1 (enExample) |
| JP (1) | JP2024503635A (enExample) |
| KR (1) | KR20230129260A (enExample) |
| CN (1) | CN116940586A (enExample) |
| AU (1) | AU2022205776A1 (enExample) |
| CA (1) | CA3206481A1 (enExample) |
| IL (1) | IL303926A (enExample) |
| WO (1) | WO2022148851A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3997103T3 (pl) | 2019-07-08 | 2025-03-24 | 3B Pharmaceuticals Gmbh | Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie |
| EP4475900A1 (en) | 2022-02-09 | 2024-12-18 | Novartis AG | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
| US20250270238A1 (en) * | 2022-05-20 | 2025-08-28 | The Governors Of The University Of Alberta | A new bifunctional linchpin that reacts selectively with cysteine residues to invoke cyclization while concurrently introducing a dotaga moiety for radiometal chelation |
| US20260083865A1 (en) * | 2022-09-07 | 2026-03-26 | 3B Pharmaceuticals Gmbh | Prostate specific membrane antigen (psma) ligands and use thereof |
| IL322552A (en) * | 2023-02-10 | 2025-10-01 | Chengdu New Radiomedicine Tech Co Ltd | Polypeptide compound and its use |
| CN118754936A (zh) * | 2023-03-27 | 2024-10-11 | 晶核生物医药科技(南京)有限公司 | 环状多肽类化合物及其应用 |
| CR20260011A (es) * | 2023-06-14 | 2026-05-15 | Mariana Oncology Inc | Péptidos dirigidos a dll3 y sus construcciones |
| JP2026521249A (ja) * | 2023-06-14 | 2026-06-29 | マリアナ オンコロジー インコーポレーテッド | Ｄｌｌ３標的化ペプチド及びその構築物 |
| AU2024304266A1 (en) * | 2023-06-14 | 2025-12-04 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| WO2025082283A1 (zh) * | 2023-10-16 | 2025-04-24 | 四川科伦博泰生物医药股份有限公司 | 环肽结构的配体化合物及其核素标记物、药物组合物及应用 |
| GB202318958D0 (en) * | 2023-12-12 | 2024-01-24 | King S College London | Compound |
| AU2025214491A1 (en) | 2024-02-01 | 2026-08-06 | Novartis Ag | Methods for treating cancer |
| WO2025179168A1 (en) * | 2024-02-22 | 2025-08-28 | Mariana Oncology Inc. | Synthesis of dll3-binding peptides |
| WO2026011104A2 (en) * | 2024-07-03 | 2026-01-08 | Trustees Of Tufts College | Radiopharmaceutical small molecule inhibitors of fibroblast activation protein for targeted therapy and diagnostic imaging of desmoplastic tumors |
| WO2026017046A1 (zh) * | 2024-07-19 | 2026-01-22 | 晶核生物医药科技(南京)有限公司 | 一种环多肽、其制备方法和应用 |
| WO2026021314A1 (zh) * | 2024-07-22 | 2026-01-29 | 山东威智知科药业有限公司 | Fap化合物及其用途 |
| WO2026056964A1 (zh) * | 2024-09-14 | 2026-03-19 | 四川科伦博泰生物医药股份有限公司 | 环肽结构的配体化合物及其核素标记物、药物组合物及应用 |
| WO2026163110A1 (en) | 2025-01-30 | 2026-08-06 | Novartis Ag | Combinations with fap targeting compounds and conjugates thereof |
| CN120590466B (zh) * | 2025-08-06 | 2026-05-12 | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 一种靶向成纤维细胞活化蛋白的化合物及其应用 |
| CN121045338B (zh) * | 2025-11-05 | 2026-05-19 | 原子高科股份有限公司 | 一种靶向caix的环肽及其制备方法与应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| JP2001518290A (ja) | 1997-09-29 | 2001-10-16 | ポイント セラピューティクス， インコーポレイテッド | インビトロでの造血細胞の刺激 |
| EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| CA2401252A1 (en) | 2000-03-17 | 2001-09-20 | Boehringer Ingelheim Pharma Kg | Human and humanized fap-alpha-specific antibodies |
| US7374898B2 (en) | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
| CA2606785A1 (en) | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| CA2681351A1 (en) | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein, and methods of use thereof |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| CN102203061A (zh) | 2008-09-25 | 2011-09-28 | 分子制药洞察公司 | 选择性seprase抑制剂 |
| WO2011040972A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| PE20171512A1 (es) | 2010-08-13 | 2017-10-20 | Roche Glycart Ag | Anticuerpos anti-fap |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| WO2016146174A1 (en) | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
| CR20180581A (es) | 2016-06-10 | 2019-02-11 | Bayer Pharma AG | Complejos radio-farmacéuticos |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| JP2021500373A (ja) | 2017-10-23 | 2021-01-07 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤 |
| CN118955620A (zh) * | 2019-07-08 | 2024-11-15 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| EP3763726A1 (en) * | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
-
2021
- 2021-01-07 EP EP21150562.3A patent/EP4050018A1/en not_active Ceased
-
2022
- 2022-01-07 CA CA3206481A patent/CA3206481A1/en active Pending
- 2022-01-07 CN CN202280019455.0A patent/CN116940586A/zh active Pending
- 2022-01-07 WO PCT/EP2022/050294 patent/WO2022148851A1/en not_active Ceased
- 2022-01-07 EP EP22700589.9A patent/EP4274836A1/en active Pending
- 2022-01-07 JP JP2023541262A patent/JP2024503635A/ja active Pending
- 2022-01-07 KR KR1020237026402A patent/KR20230129260A/ko active Pending
- 2022-01-07 IL IL303926A patent/IL303926A/en unknown
- 2022-01-07 AU AU2022205776A patent/AU2022205776A1/en active Pending
- 2022-01-07 US US18/270,904 patent/US20240115745A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022541752A5 (enExample) | ||
| IL289673B1 (en) | Compounds comprising a fibroblast activation protein ligand and use thereof | |
| JP2024503637A5 (enExample) | ||
| US5759515A (en) | Polyvalent peptide pharmaceutical applications | |
| CN102458436B (zh) | 黑皮质素受体特异性肽 | |
| JP2017534676A5 (enExample) | ||
| CA2121724A1 (en) | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | |
| AU2021204691B2 (en) | Improved pharmacokinetics and cholecystokinin-2 receptor (CCK2R) targeting for diagnosis and therapy | |
| JP2020502051A5 (enExample) | ||
| AU2024287205A1 (en) | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | |
| JP2025503451A5 (enExample) | ||
| US20250242064A1 (en) | Cxcr4-targeting compounds, and methods of making and using the same | |
| US20210330824A1 (en) | Purification method and compositions | |
| US20240100203A1 (en) | Novel cxcr4-targeting compounds | |
| AU2021204347A1 (en) | Somatostatin receptor antagonist compounds and methods of using the same | |
| ES2929507T3 (es) | Método para marcar una molécula directora biológica mediante conjugación con un radioisótopo adecuado para formación de imágenes por PET o SPECT | |
| US10548995B2 (en) | Radiolabelling method | |
| JP2949129B2 (ja) | 胃腸運動刺激活性を有するモチリン類似ポリペプチド | |
| HK1226050A1 (en) | Purification method and compositions | |
| JP2023520769A (ja) | イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト | |
| AU2024304266A1 (en) | Dll3 targeting peptides and constructs thereof | |
| RU2022101907A (ru) | Соединения, содержащие лиганд белка активации фибробластов, и их применение | |
| US20110318827A1 (en) | Cysteine-Free Efficient Technetium (Tc) or Rhenium (Re) Chelating Peptide Tags and Their Use |